Promedior, Inc.

ACTIVE

1 Dna Way, South San Francisco, California, United Stateswww.promedior.comSubsidiary51–100 employeesEstablished: 2006-01-01

Part of Roche Holding AG

Clinical Trials

10 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2006

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

83.3%

Phase 2

16.7%

Trial Status Distribution

Active, not recruiting

83.3%

Completed

16.7%

Clinical Trials

Trials sponsored by this organization (12)

A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by fibrotic tissue.

Phase 1

Active, not recruiting

Oct 2021124 participants

A study to test intravenous PRM-151 for safety and to see how PRM-151 acts in the body and blood of people with idiopathic pulmonary fibrosis (IPF) - a disorder where lung tissue becomes damaged and scarred making it difficult to breathe.

Phase 1

Active, not recruiting

Sep 2021117 participants

A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Phase 1

Active, not recruiting

Apr 2016117 participants

A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.

Phase 1

Active, not recruiting

Mar 201684 participants

A study to test intravenous PRM-151 for safety and to see how PRM-151 acts in the body and blood of people with idiopathic pulmonary fibrosis (IPF) - a disorder where lung tissue becomes damaged and scarred making it difficult to breathe.

Phase 1

Active, not recruiting

Dec 2015117 participants

A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.

Phase 1

Active, not recruiting

Dec 201584 participants

A study to test intravenous PRM-151 for safety and to see how PRM-151 acts in the body and blood of people with idiopathic pulmonary fibrosis (IPF) - a disorder where lung tissue becomes damaged and scarred making it difficult to breathe.

Phase 1

Active, not recruiting

Aug 2015117 participants

A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.

Phase 1

Active, not recruiting

Jul 201598 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations